Palvella Therapeutics' Q1 net loss widens on higher costs

Palvella Therapeutics

07/05/2026 12:58

Overview

US rare disease biopharma's Q1 net loss widened as R&D and admin costs increased

Company raised $230 mln in equity financing, ending Q1 with $261.9 mln in cash

Result Drivers

R&D SPENDING - Higher research and development expenses driven by increased manufacturing activities, headcount, and consulting services

ADMIN COSTS - General and administrative expenses rose due to increased headcount and professional services related to operating as a public company

Company press release: ID:nGNX8lydRj

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$1.20
Q1 Net Income
-$15.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Palvella Therapeutics Inc is $223.50, about 71.7% above its May 6 closing price of $130.17

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)